Physician profile
Joel Neugarten
NPI 1750466520
$248,458.17
in general payments reported to CMS, 2019-2025
15 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83K · 2020: $22K · 2021: $36K · 2022: $61K · 2023: $18K · 2024: $28K · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $3,919 · Consulting Fee: $2,290 · Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,062.50 |
| Travel and Lodging | $3,919.12 |
| Consulting Fee | $2,290.00 |
| Food and Beverage | $1,721.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $86,730.73 | 2019-2024 | Tavneos, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $68,059.14 | 2019-2024 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $43,161.88 | 2019-2024 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $20,581.20 | 2021-2023 | Lupkynis |
| Vifor Pharma, INC. | $18,181.57 | 2020-2025 | Korsuva, Veltassa |
| Fresenius USA Marketing, INC. | $4,336.49 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $4,043.75 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $1,948.33 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $350.00 | 2024 | |
| Alnylam Pharmaceuticals INC. | $320.83 | 2020 | |
| Beigene USA, INC. | $290.00 | 2024 | |
| Vifor (International) LTD. | $191.67 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $172.58 | 2025 | Voyxact |
| Glaxosmithkline, LLC. | $90.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Neugarten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.